CenExel Clinical Research | Anaheim Clinical Trials
Status and phase
Conditions
Treatments
About
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). Part A of the study, the sponsor is only researching trevogrumab. Part B of the study the sponsor is researching trevogrumab, garetosmab, and Wegovy either alone or in different combinations with each other. Part A of the study is focused on healthy participants. Part B of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B of the study is to see how safe and effective the study drug is when combined with Wegovy.
Parts A and B of the study are looking at several other research questions, including:
Full description
Part A Healthy Volunteers
Part B (starts after treatment for Part A has completed) Participants with Obesity
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria
Part A
Male or female participants age ≥18 to ≤55 years of age at the time of screening
BMI ≥18 and ≤32 kg/m2, at the screening visit
Part B
Male or female participants ≥18 to ≤80 years of age at the time of screening
BMI ≥30 kg/m2
History of 1 or more self-reported unsuccessful dietary attempts to lose weight
Key Exclusion Criteria
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Primary purpose
Allocation
Interventional model
Masking
624 participants in 10 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal